Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Nociceptin, NOPR and Sleep/Wake Control

Award Number: R01NS136808
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/15/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2029

Group Awards By:

View Award Description

Nociceptin, NOPR and Sleep/Wake Control - PROJECT SUMMARY The widespread misuse of prescription opioids, opioid addiction, and overdose has underscored the urgent need to develop effective, non-addicting medications to treat chronic pain, a leading cause of insomnia. Agonists at the nociceptin/orphanin FQ (N/OFQ) receptor (NOPR) have shown promise as modulators of the antinociceptive and rewarding effects of opioids. We have found that two different NOPR agonists potently induced sleep and increased EEG delta power in rats, mice, and non-human primates, suggesting that the N/OFQ-NOPR system may have a previously unrecognized role in sleep/wake regulation. Since our studies used synthetic compounds, the hypothesis to be tested in this proposal is that the N/OFQ-NOPR system is a component of the endogenous sleep/wake regulatory system. First, we will evaluate whether disruption of endogenous NOPR tone affects the regulation of activity, sleep/wake and/or body temperature (Tb) using a novel, inducible NOPR (iNOPR) KO mouse strain in which NOPR can be deleted throughout the brain by systemic administration of tamoxifen. We will expand on our initial results which indicate that, not only do iNOPR KO mice fail to respond to NOPR agonism by increasing NREM sleep, they exhibit a partial insomnia under baseline conditions with longer wake bouts during the major sleep period. We will then begin to establish the neuroanatomical foundation for the phenotypes identified in the global deletion study and for subsequent circuit-based studies by determining the chemotypes of neurons activated by NOPR agonism. First, we will determine NOPR expression in neuronal populations known to be involved in sleep/wake control. Global assessment of NOP agonist-induced c-Fos expression showed that two of 316 brain areas stood out as having increased Fos expression: the lateral habenula (LHb) and the anterodorsal preoptic and adjacent parastrial (ADP/PS) nuclei. We will follow up by obtaining a global view on NOP agonist-induced Fos expression in Oprl1 KI-eGFP and Pnoc-IRES-Cre (Prepronociceptin-IRES-Cre) mice and use other genetic markers to further characterize and quantify the Fos+ neurons. Next, we will determine whether local NOPR deletion affects activity, sleep/wake and/or Tb by injecting a Cre-dependent virus into candidate brain regions in NOPRlox/lox mice, particularly focusing on the LHb and ADP/PS nuclei. We will then chemogenetically activate glutamatergic and NOPR+ neurons in the LHb to determine whether these cells affect activity, sleep/wake and/or Tb and use the Fos-TRAP method to chemogenetically reactivate LHb and ADP/PS neurons labelled after NOPR agonist treatment. The information obtained will further our understanding of the role of the N/OFQ – NOP system in sleep/wake control and enable us to develop a circuit-based model to understand the effects on NOPR agonism on sleep/wake physiology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $826,035 )
2026	2026	SRI INTERNATIONAL	333 RAVENSWOOD AVE	MENLO PARK	CA	94025	SAN MATEO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	2/2/2026	NON-COMPETING CONTINUATION	$826,035
														Subtotal = $826,035

Issue Date FY: 2025 ( Subtotal = $839,815 )
2025	2025	SRI INTERNATIONAL	333 RAVENSWOOD AVE	MENLO PARK	CA	94025	SAN MATEO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	3/14/2025	NON-COMPETING CONTINUATION	$839,815
														Subtotal = $839,815

Issue Date FY: 2024 ( Subtotal = $952,099 )
2024	2024	SRI INTERNATIONAL	333 RAVENSWOOD AVE	MENLO PARK	CA	94025	SAN MATEO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	3/1/2024	NEW	$952,099
														Subtotal = $952,099

Grand Total All Awards = $2,617,949

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Nociceptin, NOPR and Sleep/Wake Control

Award Number: R01NS136808

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/15/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer